<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274907</url>
  </required_header>
  <id_info>
    <org_study_id>M19-700</org_study_id>
    <nct_id>NCT04274907</nct_id>
  </id_info>
  <brief_title>A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression</brief_title>
  <official_title>A Phase 1b Study of Venetoclax in Combination With Pembrolizumab in Subjects With Previously Untreated NSCLC Whose Tumors Have High PD-L1 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in
      the tissues of the lung. It is the most common form of lung cancer, accounting for around 85%
      of lung cancers. The purpose of this study is to evaluate the safety and efficacy (how well
      the study drug works against the disease) of Venetoclax in combination with Pembrolizumab in
      participants with NSCLC.

      Venetoclax is a drug that kills cancer cells by blocking a protein (part of a cell) that
      allows cancer cells to stay alive. Pembrolizumab is approved drug for the treatment of NSCLC.
      It works with your immune system to help fight certain cancers. The study is split into two
      portions - dose escalation and randomization. Participants are assigned one of the three
      treatment groups to receive pembrolizumab alone or in combination with venetoclax. Each group
      receives a different treatment. Participants who are at least 18 years of age with a
      diagnosis of NSCLC will be enrolled. Around 100 participants will be enrolled in the study in
      approximately 44 sites across United States.

      Participants will receive intravenous (IV) infusion of pembrolizumab alone or in combination
      with oral venetoclax tablets.

      There will be higher treatment burden for participants in this trial compared to their
      standard of care. Participants will attend regular visits during the course of the study at a
      hospital or clinic. The effect of the treatment will be checked by medical assessments, blood
      tests, checking for side effects and completing questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">January 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>DLTs are adverse events that are considered to have a reasonable possibility of relationship to the administration of venetoclax and pembrolizumab and cannot be attributed by the investigator to a clearly identifiable cause such as disease progression, concurrent illness or concomitant medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the Sum of the Longest Diameter (SLD)</measure>
    <time_frame>Up to 35 Cycles (Each Cycle is 21 Days)</time_frame>
    <description>Change in the SLD is assessed by exposure-response modeling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Venetoclax</measure>
    <time_frame>Up to Cycle 1 (Each Cycle is 21 Days)</time_frame>
    <description>Maximum plasma concentration (Cmax) of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax</measure>
    <time_frame>Up to Cycle 1 (Each Cycle is 21 Days)</time_frame>
    <description>Time to maximum observed plasma concentration (Tmax) of venetoclax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve Over Time from 0 to 24 (AUC0-24) of Venetoclax in Plasma</measure>
    <time_frame>Up to Cycle 1 (Each Cycle is 21 Days)</time_frame>
    <description>Area Under the Plasma Concentration-time Curve (AUC) from 0-24 (AUC0-24)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 35 Cycles (Each Cycle is 21 Days)</time_frame>
    <description>ORR will be defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase: Venetoclax + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of venetoclax in combination with pembrolizumab dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomization Phase: Venetoclax + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive venetoclax at dose levels determined in the dose escalation phase in combination with pembrolizumab dose A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomization Phase: Pembrolizumab Monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive pembrolizumab dose A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet: Oral</description>
    <arm_group_label>Dose Escalation Phase: Venetoclax + Pembrolizumab</arm_group_label>
    <arm_group_label>Randomization Phase: Venetoclax + Pembrolizumab</arm_group_label>
    <other_name>Venclexta</other_name>
    <other_name>ABT-199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Intravenous (IV) Infusion</description>
    <arm_group_label>Dose Escalation Phase: Venetoclax + Pembrolizumab</arm_group_label>
    <arm_group_label>Randomization Phase: Pembrolizumab Monotherapy</arm_group_label>
    <arm_group_label>Randomization Phase: Venetoclax + Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically documented advanced or metastatic NSCLC with no known epidermal growth
             factor receptor (EGFR) sensitizing (activating) mutation or anaplastic lymphoma kinase
             (ALK) translocation.

          -  At least one measurable lesion as defined by Response Evaluation Criteria in Solid
             Tumours (RECIST) 1.1

          -  High PD-L1 tumor expression (tumor proportion score &gt;= 50%) as determined by a Food
             and Drug Administration (FDA)-approved test.

          -  Willing to provide tissue biopsy sample prior to start of study and during treatment.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

        Exclusion Criteria:

          -  Received prior systemic treatment for their advanced or metastatic NSCLC. Participants
             who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant
             therapy was completed at least 6 months prior to the diagnosis of metastatic disease.

          -  History of or ongoing interstitial lung disease or pneumonitis that required oral or
             intravenous (IV) steroids.

          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.,
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
             form of systemic treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham /ID# 214180</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 216984</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Jude Hospital dba St Joseph /ID# 212360</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icri /Id# 217071</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute - Orlando /ID# 214444</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's Mountain States Tumor Institute - Boise /ID# 217073</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine /ID# 214322</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2927</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center /ID# 212448</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 214319</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hosp /ID# 214952</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology /ID# 214954</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Kansas Med Ctr /ID# 216897</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ashland-Bellefonte Cancer Ctr /ID# 218511</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville /ID# 215195</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Maine Medical Center /ID# 216107</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology /ID# 214131</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044-3128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute /ID# 216986</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 216385</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ of Mississippi Med Ctr /ID# 216429</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216-4500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 212355</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Methodist Estabrook Cancer Center /ID# 216910</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114-4108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center /ID# 216754</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6840</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack Univ Med Ctr /ID# 216484</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System /ID# 217067</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960-6136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Overlook Medical Center /ID# 219108</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901-3533</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 218077</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center /ID# 216911</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute /ID# 216800</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219-2364</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland /ID# 212241</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University - The James /ID# 212298</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology and Hematology Care - Westside Portland /ID# 215497</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital /ID# 214363</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prisma Health /ID# 217946</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605-4255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Ctr /ID# 217076</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists /ID# 215496</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists /ID# 214328</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute /ID# 216915</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation /ID# 217913</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties /ID# 218484</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer (NSCLC)</keyword>
  <keyword>Cancer</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>PD-L1 Expression</keyword>
  <keyword>ABT-199</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

